ID
38479
Descripción
Study ID: 108062 Clinical Study ID: 108062 Study Title: A three part, staggered cohort, open-label and double blind, randomized, placebo controlled study to investigate the efficacy, safety, tolerability and pharmacokinetics of eltrombopag, a thrombopoietin receptor agonist, in previously treated pediatric patients with chronic idiopathic thrombocytopenic purpura (ITP). Eltrombopag PETIT: Eltrombopag in PEdiatric patients with Thrombocytopenia from ITP Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00908037 https://clinicaltrials.gov/ct2/show/NCT00908037 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 2 Study Recruitment Status: Completed Generic Name: eltrombopag, Placebo Trade Name: N/A Study Indication: Purpura, Thrombocytopaenic, Idiopathic The study consists of a screening, Day 1 and three parts. All subjects were supposed to receive 24 weeks (6 months) of eltrombopag treatment during Part 2/3. Screening period: Up to 28 days prior to Day 1 of treatment. Day 1 Part 1 (Dose Finding Phase): A 24-week (6 months) open label treatment period for 5 subjects in each age cohort. (short: P1W1-P1W7, P1W8-23, P1W24/EW). A safety, PK and platelet count review took place after 12 weeks (3 months) of treatment. Subjects in the Dose Finding Phase did not participate in the Randomized Period. Part 2 (Randomized Period): A 7-week randomized, double-blind, placebo-controlled period involving 18 subjects per cohort (short: P2W1-P2W7). Part 3: An open-label treatment period where subjects randomized to eltrombopag in Part 2 received an additional 17 weeks of eltrombopag in Part 3 and subjects randomized to placebo in Part 2 received 24 weeks of eltrombopag in Part 3 (short: P3W8-P3W23, P3W24/EW, P3W8-30, P3W31/EW). Follow-up: 4 weeks following the last dose of eltrombopag (short: FUW1- FUW4). Additional ocular examinations were performed at 12 and 24 weeks (3 and 6 months) after the last dose of eltrombopag (short: FUM3, FUM6). The subjects were enrolled in 3 cohorts: Cohort 1: Subjects between 12 and 17 years old (<18 years of age at Day 1). Cohort 2: Subjects between 6 and 11 years old (<12 years of age at Day 1). Cohort 3: Subjects between 1 and 5 years old (<6 years of age at Day 1). The enrollment was started with the oldest cohort (Cohort 1). The younger cohorts were not enrolled until safety, PK and platelet counts had been reviewed in the older cohort(s). This document contains the blood products and blood supportive care products and status of treatment blind form. It has to be filled in for Logs and repeats.
Link
https://clinicaltrials.gov/ct2/show/NCT00908037
Palabras clave
Versiones (2)
- 21/10/19 21/10/19 -
- 5/12/19 5/12/19 - Sarah Riepenhausen
Titular de derechos de autor
GlaxoSmithKline
Subido en
21 de octubre de 2019
DOI
Para solicitar uno, por favor iniciar sesión.
Licencia
Creative Commons BY-NC 3.0
Comentarios del modelo :
Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.
Comentarios de grupo de elementos para :
Comentarios del elemento para :
Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.
Effects of eltrombopag in children with chronic idiopathic thrombocytopenic purpura, NCT00908037
Logs and repeats: Blood products and blood supportive care products and status of treatment blind
Descripción
Blood products and blood supportive care products
Alias
- UMLS CUI-1
- C0456388
- UMLS CUI-2
- C0018938
Descripción
In the original form this item is hidden.
Tipo de datos
integer
Alias
- UMLS CUI [1]
- C2348184
Descripción
If you tick "Other Blood Product" or "Other Blood Supportive Care Product", please specify in the appropriate items.
Tipo de datos
text
Alias
- UMLS CUI [1]
- C0456388
- UMLS CUI [2]
- C0018938
Descripción
Other Blood Product
Tipo de datos
text
Alias
- UMLS CUI [1,1]
- C0205394
- UMLS CUI [1,2]
- C0456388
- UMLS CUI [1,3]
- C2348235
Descripción
Other Blood Supportive Care Product
Tipo de datos
text
Alias
- UMLS CUI [1,1]
- C0205394
- UMLS CUI [1,2]
- C0018938
- UMLS CUI [1,3]
- C2348235
Descripción
Cumulative Quantity or Dose
Tipo de datos
float
Alias
- UMLS CUI [1]
- C2986497
Descripción
Units
Tipo de datos
text
Alias
- UMLS CUI [1,1]
- C1519795
- UMLS CUI [1,2]
- C0456388
- UMLS CUI [2,1]
- C1519795
- UMLS CUI [2,2]
- C0018938
Descripción
day month year 00:00-23:59
Tipo de datos
partialDatetime
Alias
- UMLS CUI [1]
- C3897500
Descripción
day month year 00:00-23:59
Tipo de datos
partialDatetime
Alias
- UMLS CUI [1]
- C3899266
Descripción
Status of treatment blind
Alias
- UMLS CUI-1
- C0749659
- UMLS CUI-2
- C2347038
Descripción
If yes, complete the Adverse Event form and/or Investigational Product forms as appropriate. Fill in also date and reason of blind broken in the appropriate items.
Tipo de datos
text
Alias
- UMLS CUI [1]
- C3897431
Descripción
day month year
Tipo de datos
date
Alias
- UMLS CUI [1,1]
- C3897431
- UMLS CUI [1,2]
- C0011008
Descripción
Reason blind broken
Tipo de datos
text
Alias
- UMLS CUI [1,1]
- C3897431
- UMLS CUI [1,2]
- C0392360
Descripción
Other reason blind broken, specification
Tipo de datos
text
Alias
- UMLS CUI [1,1]
- C3897431
- UMLS CUI [1,2]
- C0392360
- UMLS CUI [1,3]
- C3845569
- UMLS CUI [1,4]
- C2348235
Similar models
Logs and repeats: Blood products and blood supportive care products and status of treatment blind
C0018938 (UMLS CUI-2)
C0018938 (UMLS CUI [2])
C0456388 (UMLS CUI [1,2])
C2348235 (UMLS CUI [1,3])
C0018938 (UMLS CUI [1,2])
C2348235 (UMLS CUI [1,3])
C0456388 (UMLS CUI [1,2])
C1519795 (UMLS CUI [2,1])
C0018938 (UMLS CUI [2,2])
C2347038 (UMLS CUI-2)
C0011008 (UMLS CUI [1,2])
C0392360 (UMLS CUI [1,2])
C0392360 (UMLS CUI [1,2])
C3845569 (UMLS CUI [1,3])
C2348235 (UMLS CUI [1,4])